GSK to acquire Cellzome

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will acquire the 80.02% of proteomics company Cellzome AG (Heidelberg, Germany) it does not already own for L61 million ($98 million) in cash. GSK said Cellzome's proteomic mass spectrometry and screening capabilities will allow the pharma to reduce compound attrition during development. ...